Nurix Therapeutics Inc 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Nurix Therapeutics Inc 's ROA in the third quarter of 2026?
Nurix Therapeutics Inc achieved a return on average assets (ROA) of 38.61 % in its third quarter of 2026 a new company high.

ROA has improved compared to -57.32% in the second quarter of 2026, due to net income growth.

However, within the Healthcare sector 26 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Aug 31 2026 quarter, so far to 3935, from total ROA ranking in the second quarter of 2026 at 4542.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Aug 31 2026) III. Quarter	(May 31 2026) II. Quarter	(Feb 28 2026) I. Quarter	(Nov 30 2025) IV. Quarter	(Aug 31 2025) III. Quarter
Y / Y Total Assets Change	128.78 %	-9.47 %	3.43 %	2.81 %	1.82 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	295	-341	-295	-264	-245
Return On Assets (TTM)	38.61 %	-57.32 %	-48.44 %	-43.76 %	-40.82 %
NRIX's Total Ranking	# 3935	# 4542	# 3941	# 3890	# 3983
Total Assets (TTM) in million	1,195	536	636	688	522
Seq. Total Assets Change	123.19 %	-15.81 %	-7.56 %	31.71 %	-11.68 %
Seq. Net Income Change	-	-	-	-	-

NRIX's 5 Years Annual ROA >> Back to NRIX Management Effectiveness >> Compare NRIX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 15
Sector	# 27
Overall	# 92

Return On Assets Statistics
High	Average	Low
38.61 %	-34.04 %	-57.32 %
(Aug 31 2026)		(May 31 2026)

Financial Statements
Nurix Therapeutics Inc 's Assets	$ 1,195 million	NRIX's Balance sheet
Nurix Therapeutics Inc 's Income	$ 550 million	Quarterly NRIX's Income Statement
NRIX's Income by Division		See NRIX's Income by Division

Annual Return On Assets	(Nov 30 2025) FY 2025	(Nov 30 2024) FY 2024	(Nov 30 2023) FY 2023	(Nov 30 2022) FY 2022	(Nov 30 2021) FY 2021
Y / Y Total Assets Change	2.81 %	88.23 %	-14.82 %	-12.43 %	20.29 %
Total Assets in million	688	669	356	417	477
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-264	-194	-144	-180	-117
Annual Return On Assets	-38.43 %	-28.92 %	-40.48 %	-43.2 %	-24.58 %

NRIX's 5 Years Annual ROA >> Back to NRIX Management Effectiveness >> Compare NRIX ROA to its Competitors

More Return On Assets Ratios
NRIX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NRIX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NRIX's Competitors
Subscribers only: Roa for Nurix Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for NRIX's Customers

You may also want to know
NRIX's Roi	NRIX's Inventory Turnover Ratio	NRIX's Growth Rates	NRIX's Dividend Comparisons
	NRIX's Profitability Ratios	NRIX's Asset Turnover Ratio	NRIX's Dividend Growth
NRIX's Roe	NRIX's Valuation Ratios	NRIX's Financial Strength Ratios	NRIX's Dividend Payout Ratio

Companies with similar Return On Assets at Aug 31 2026, within Healthcare Sector	ROA
Exelixis Inc	63.88 %
Rigel Pharmaceuticals Inc	59.56 %
Alnylam Pharmaceuticals Inc	46.08 %
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %

Date modified: 2026-10-14T16:57:13+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.